Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imugene ( (AU:IMU) ) has provided an announcement.
Imugene Limited has applied to the ASX for quotation of new fully paid ordinary shares that have been issued following the exercise of options or conversion of other convertible securities. The newly issued securities, dated 26 March 2026 and 30 March 2026, formalise prior equity commitments and marginally expand the company’s quoted capital base, potentially improving liquidity for investors and supporting ongoing funding flexibility.
The application is lodged as a new announcement under Appendix 2A, confirming that all required securities have already been created and are now seeking admission to trading on the exchange. While the filing is largely procedural, it signals continued utilisation of equity-linked instruments in Imugene’s capital structure, a common practice for growth-stage biotech firms balancing dilution with the need for development capital.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an Australia-based biotechnology company listed on the ASX under the code IMU. The company focuses on developing immuno-oncology therapies, leveraging innovative platforms to target various cancers and enhance the body’s immune response against tumours.
Average Trading Volume: 1,671,394
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$49.98M
Find detailed analytics on IMU stock on TipRanks’ Stock Analysis page.